loading page

COVID-19, Acute Lymphoblastic Leukemia and Down Syndrome: A Short Review and a Case Report
  • +3
  • Ahmed Arafat,
  • Dinara Sadykova,
  • Ayrat Ziatdinov,
  • Svetlana Senek,
  • Natalya Samoilova,
  • Tamara Makarova
Ahmed Arafat
Kazan State Medical University
Author Profile
Dinara Sadykova
Kazan State Medical University
Author Profile
Ayrat Ziatdinov
Kazan State Medical University
Author Profile
Svetlana Senek
Kazan State Medical University
Author Profile
Natalya Samoilova
Kazan State Medical University
Author Profile
Tamara Makarova
Kazan State Medical University
Author Profile

Abstract

In late December 2019, Chinese citizens of the city of Wuhan, China, had shown symptoms of viral pneumonia that were not very common, with various presentations with different grades of severity, and poor response to the regular treatment. With tremendous clinical and research work, the causative of the disease outbreak has been identified as COVID-19 and has been recognized as the novel coronavirus (SARS-CoV-2), which later continued to make the headlines when the World Health Organization announced it as a pandemic on March 11, 2020, after it had hit many parts in the globe with worrying rates of morbidity and mortality. Although available data has expressed that moderate or even mild forms of the disease are expected amongst most of the pediatrics cases, very limited data are available on the prognosis and the complications of the disease on the immunocompromised, especially oncology patients. We report a case of relapsed Precursor B-cell acute lymphoblastic leukemia (ALL) of a child with Down syndrome (DS) and COVID-19 and outline the treatment regimen that we used.